SecBot

SecBot
NYSE· Pharmaceutical Preparations· Inc. IL· CIK 0000001800

ABT

ABBOTT LABORATORIES
$96.46 ▼ -0.24%
Prev close $96.69
Market cap$171.0B
ConsensusBuy
12-mo target$120.58 (+25.0%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)32 New Institutional Positions18 Institutional ExitsCongressional Activity (3) Biotech & Drug Discovery
Snapshot
The big-picture read on ABT right now — valuation, ownership and activity at a glance.
Market Cap
$171.0B
Cap Size
Large Cap
Analyst Consensus
Strong Buy (76%)
Inst. Holders
50 funds
Inst. Value
$90.7B
Inst. Activity
32 buys / 18 sells
Insider Activity
$1.3M buy / $47.3M sell
Insider Net $
-$46.0M
Social Sentiment
75° Bullish
SEC Reports
20
Congressional
15 trades
Price chart 30d -12.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 SEC
🔒 Fresh report (last 24h) — subscribers only
Oct 2, 2026 SEC
🔒 Fresh report (last 24h) — subscribers only
Sep 30, 2026 Event
Rapacon v. Abbott Laboratories
Court ruling (cand) — Docket: 4:26-cv-00311
Sep 25, 2026 short_volume
Short Volume: ABT — 59.9% short (1.8M / 2.9M)
Short: 1,760,231 | Exempt: 770 | TRF Vol: 2,940,648 | Short Ratio: 59.9% | Off-exchange volume (dark
Sep 23, 2026 Insider
Conroy Kevin T surrendered for taxes 52,507 shares
Director @ $103.99 ($5.5M)
Sep 2, 2026 Insider
MCCOY JOHN A. JR. sold 27 shares
VICE PRESIDENT AND CONTROLLER @ $109.54 ($3.0K)
Sep 1, 2026 Insider
Boudreau Philip P surrendered for taxes 388 shares
EVP AND CFO @ $110.36 ($42.8K)
Jul 30, 2026 Congress
Rich McCormick sell
$1,001 - $15,000 — House
Analyst ratings buy % +13.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Buy 76% rate it Buy or better · 33 analysts
Strong Buy 12 36% Buy 13 39% Hold 8 24% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Oct 2, 2026Rothschild & CoUPGRADEBuy 58%
Sep 8, 2026TD CowenREITERATEBuy 56%
Aug 25, 2026TD CowenMAINTAINBuy 56%
Aug 21, 2026TD CowenMAINTAINBuy 56%
Aug 14, 2026CitigroupMAINTAINBuy 55%
Aug 13, 2026Wolfe ResearchUPGRADEOutperform 52%
Jul 28, 2026UBSMAINTAINBuy 55%
Jul 17, 2026CitigroupMAINTAINBuy 55%
Jul 17, 2026Piper SandlerREITERATEOverweight 54%
Jul 17, 2026JP MorganMAINTAINOverweight 55%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 2026121380076%
Aug 1, 2026111390073%
Jul 1, 20261114100071%
Jun 1, 20261014100071%
May 1, 20261015100071%
Apr 1, 2026101690074%
Mar 1, 20261015100071%
Feb 1, 20261015100071%
Price targets
Where 25 covering analysts think ABT trades over the next 12 months.
$120.58 +25.0% upside Strong Buy
Current$96.46 Low$103.00 Median$120.00 High$135.00 25 analysts
$103.00$135.00
Analyst rating Buy· 1.5/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
75°
Bullish
BearishNeutralBullish
12 mentions 8 bullish 0 bearish 4 neutral
Recent posts
wallstreetbets Bullish 2mo ago
Medtech, Medtronic are gaining
▲ 1 · 💬 0· ⚡ 0.5
investing Neutral 3mo ago
Rotation into consumer staples/defensives - best plays?
▲ 1 · 💬 0· ⚡ 0.5
wallstreetbets Neutral 4mo ago
$500 to $5mil Project - NKE $50C Jul17 + ABT $100C Jul17 - Full DDs
▲ 1 · 💬 1· ⚡ 0.5
stockmarket Bullish 4mo ago
9 oversold alerts in S&P today. AMD up 82% vs market in 20 days
▲ 1 · 💬 0· ⚡ 0.4
stocks Neutral 4mo ago
ABOTT(ABT) opinions
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 5 bullish, 1 bearish, 1 mixed, 13 neutral · avg impact 3.1/10.
BULLISHANALYST-UPGRADE3/10
Baird initiates ABT at Outperform — PT $121 (+33%)
Jul 1, 2026
BULLISHANALYST-UPGRADE4/10
🔒 Fresh report (last 24h) — subscribers only
Oct 2, 2026
BULLISHANALYST-UPGRADE4/10
🔒 Fresh report (last 24h) — subscribers only
Oct 2, 2026
NEUTRALCOURT-RULING1/10
This is a routine procedural order in a consumer class action against Abbott Diabetes Care and Abbot
Sep 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
Enforcement
Rapacon v. Abbott Laboratories
Court ruling (cand) — Docket: 4:26-cv-00311
Sep 29, 2026
Enforcement
Ghosh v. Abbott Laboratories, Inc. et al
Court ruling (hid) — Docket: 1:26-cv-00264
Sep 25, 2026
short_volume
Short Volume: ABT — 59.9% short (1.8M / 2.9M)
Short: 1,760,231 | Exempt: 770 | TRF Vol: 2,940,648 | Short Ratio: 59.9% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
short_volume
Short Volume: ABT — 67.6% short (1.6M / 2.4M)
Short: 1,593,168 | Exempt: 2,147 | TRF Vol: 2,357,380 | Short Ratio: 67.6% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
dividend
Abbott declares 411th consecutive quarterly dividend
ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$1.42$1.41–$1.449.2%+0.0%7↑ 10↓$13.0B22
Next Q$1.64$1.59–$1.679.2%+0.0%15↑ 0↓$13.5B22
Current FY$5.52$5.48–$5.577.2%+0.0%5↑ 1↓$50.2B26
Next FY$6.07$5.88–$6.209.9%+0.0%3↑ 2↓$54.5B26
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$1.420—
7d ago$1.420+0.000
30d ago$1.420+0.000
60d ago$1.419+0.001
90d ago$1.421-0.001
Institutional ownership
Which big funds own ABT (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $90.7B total value (998,680,614 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
BlackRock, Inc.152,563,476$13.8B15.3%—
VANGUARD CAPITAL MANAGEMENT LLC113,750,994$10.3B11.4%—
STATE STREET CORP80,926,234$7.3B8.1%—
CHARLES SCHWAB INVESTMENT MANAGEMENT INC59,674,507$5.4B6.0%ADD +31.2%
VANGUARD PORTFOLIO MANAGEMENT LLC49,017,866$4.4B4.9%—
GEODE CAPITAL MANAGEMENT, LLC39,219,337$3.5B3.9%—
Capital Research Global Investors36,908,990$3.3B3.7%TRIM -25.8%
Capital International Investors34,654,113$3.1B3.5%—
MORGAN STANLEY26,611,315$2.4B2.7%—
NORGES BANK23,354,911$2.1B2.3%NEW
Recent position changes
FundActionPrevCurrentChangeValue
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD45,500,05559,674,507+31.2%$5.4B
Capital Research Global InvestorsTRIM49,775,36236,908,990-25.8%$3.3B
NORGES BANKNEW—23,354,911—$2.1B
JPMORGAN CHASE & COTRIM26,767,09915,095,898-43.6%$1.4B
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD5,522,22210,897,178+97.3%$988.8M
FLOSSBACH VON STORCH SEADD7,858,4439,950,828+26.6%$902.9M
CITADEL ADVISORS LLCDOUBLED1,915,8468,597,227+348.7%$780.1M
WELLINGTON MANAGEMENT GROUP LLPTRIM27,070,5188,304,709-69.3%$753.6M
UBS Group AGTRIM12,152,7657,356,093-39.5%$667.5M
MARSHALL WACE, LLPDOUBLED2,010,9385,542,438+175.6%$502.9M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
22 insiders, 50 transactions. Net -$46.0M — $1.3M bought, $47.3M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 23, 2026Conroy Kevin TDirectorTAX W/H52,507$103.99$5.5M
Sep 2, 2026MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLERSELL27$109.54$3.0K
Sep 1, 2026Boudreau Philip PEVP AND CFOTAX W/H388$110.36$42.8K
Sep 1, 2026MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLERTAX W/H52$110.36$5.7K
Aug 25, 2026Ford Robert BCHAIRMAN AND CEOEXERCISE151,869$44.40$6.7M
Aug 25, 2026Ford Robert BCHAIRMAN AND CEOSELL218,535$115.57$25.3M
Aug 25, 2026Ford Robert BCHAIRMAN AND CEOSELL180,297$116.19$20.9M
Aug 25, 2026Ford Robert BCHAIRMAN AND CEOEXERCISE246,963$59.94$14.8M
Aug 12, 2026Morrone Louis H.EXECUTIVE VICE PRESIDENTI12$107.99$1.3K
Aug 11, 2026Morrone Louis H.EXECUTIVE VICE PRESIDENTSELL5,850$109.83$642.5K
Congressional trades
ABT trades disclosed by members of Congress, with disclosure delay.
9 members · 7 buys / 7 sells
DateMemberPartyChamberTypeAmountAssetDisclosed
Jul 30, 2026Rich McCormickRHOUSESELL$1,001 - $15,000Abbott LaboratoriesAug 17, 2026(19d)
Jul 14, 2026Rick AllenRHOUSESELL$15,001 - $50,000Abbott LaboratoriesAug 19, 2026(37d)
Jul 8, 2026Rick LarsenDHOUSESELL$1,001 - $15,000Abbott LaboratoriesJul 13, 2026(6d)
Jun 16, 2026Gilbert CisnerosDHOUSEBUY$1,001 - $15,000Abbott LaboratoriesJul 3, 2026(18d)
Jun 12, 2026Rich McCormickRHOUSEBUY$1,001 - $15,000Abbott LaboratoriesJul 10, 2026(29d)
Jun 12, 2026Rich McCormickRHOUSEBUY$1,001 - $15,000Abbott LaboratoriesJul 10, 2026(29d)
Jun 2, 2026Ro KhannaDHOUSEBUY$1,001 - $15,000Abbott LaboratoriesJul 8, 2026(37d)
May 27, 2026Josh GottheimerDHOUSESELL$1,001 - $15,000Abbott LaboratoriesJun 4, 2026(9d)
Mar 24, 2026Laura FriedmanDHOUSEEXCHANGE$1,001 - $15,000Abbott LaboratoriesApr 20, 2026(28d)
Mar 19, 2026Rich McCormickRHOUSEBUY$1,001 - $15,000Abbott LaboratoriesApr 8, 2026(21d)
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ABT.
Shares short
19,911,199
Settlement Sep 15, 2026
Change vs prior
-10.0%
Semi-monthly cycle
Days to cover
2.6
At avg daily volume
Of shares outstanding
≈1.1%
Estimate — not % of float
All ABT filing & press-release reports (23)